S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61
S&P 500   3,911.74
DOW   31,500.68
QQQ   294.61

Gelesis Stock Forecast, Price & News

-0.09 (-5.33%)
(As of 06/24/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
804,427 shs
Average Volume
156,408 shs
Market Capitalization
$115.82 million
P/E Ratio
Dividend Yield
Price Target
30 days | 90 days | 365 days | Advanced Chart

Receive GLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Gelesis and its competitors with MarketBeat's FREE daily newsletter.

GLS Stock Forecast (MarketRank)

Overall MarketRank

0.33 out of 5 stars

Medical Sector

1323rd out of 1,411 stocks

Pharmaceutical Preparations Industry

646th out of 672 stocks

Analyst Opinion: 0.0Community Rank: 0.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
Gelesis logo

About Gelesis (NYSE:GLS)

Gelesis Holdings Inc., a commercial stage biotherapeutics company, developing a biomimicry to treat the genesis of obesity and GI-related chronic diseases. The company also provides PLENITY, an orally administered, non-stimulant, and non-systemic aid for weight management. In addition, it offers a product for obesity and overweight and a pipeline with potential therapies for non-alcoholic fatty liver disease/non-alcoholic steatohepatitis, type 2 diabetes, and GS500 for Functional Constipation. Gelesis Holdings Inc. was incorporated in 2006 and is headquartered in Boston, Massachusetts.

GLS Stock News Headlines

Gelesis Holdings Inc (GLS)
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End


Net Income
$-12.90 million
Pretax Margin


Sales & Book Value

Annual Sales
$11.19 million
Book Value
($7.76) per share


Free Float
Market Cap
$115.82 million
Not Optionable

Gelesis Frequently Asked Questions

How has Gelesis' stock performed in 2022?

Gelesis' stock was trading at $6.53 at the beginning of 2022. Since then, GLS stock has decreased by 75.5% and is now trading at $1.60.
View the best growth stocks for 2022 here

When is Gelesis' next earnings date?

Gelesis is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Gelesis

How were Gelesis' earnings last quarter?

Gelesis Holdings, Inc. (NYSE:GLS) issued its earnings results on Thursday, May, 12th. The company reported ($0.10) earnings per share for the quarter. The company had revenue of $7.51 million for the quarter.
View Gelesis' earnings history

What guidance has Gelesis issued on next quarter's earnings?

Gelesis updated its FY 2022 earnings guidance on Thursday, June, 9th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $58.00 million-$58.00 million.

Who are Gelesis' key executives?

Gelesis' management team includes the following people:
  • Mr. Yishai Zohar, Founder, Pres, CEO & Director (Age 59, Pay $689.95k)
  • Mr. Elliot Maltz CPA, CFO & Treasurer (Age 37, Pay $486.26k)
  • Dr. David Pass Pharm.D., COO & Chief Commercial Officer (Age 53)
  • Mr. David Abraham J.D., Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 56, Pay $494.73k)
  • Dr. Elaine Chiquette Pharm.D., Chief Scientific Officer (Age 55)
  • Dr. Harry L. Leider FACPE, M.B.A., M.D., MBA, Chief Medical Officer (Age 63)
  • Ms. Joy Bauer M.S., MS, RDN, Chief Nutrition Officer of Plenity

What is Gelesis' stock symbol?

Gelesis trades on the New York Stock Exchange (NYSE) under the ticker symbol "GLS."

Who are Gelesis' major shareholders?

Gelesis' stock is owned by many different institutional and retail investors. Top institutional investors include Neuberger Berman Group LLC (1.61%), Vanguard Group Inc. (1.16%), BlackRock Inc. (0.82%), Beacon Pointe Advisors LLC (0.16%), State Street Corp (0.16%) and Northern Trust Corp (0.11%).
View institutional ownership trends for Gelesis

Which major investors are buying Gelesis stock?

GLS stock was bought by a variety of institutional investors in the last quarter, including Neuberger Berman Group LLC, Vanguard Group Inc., BlackRock Inc., Beacon Pointe Advisors LLC, State Street Corp, Northern Trust Corp, Northeast Financial Consultants Inc, and Goldman Sachs Group Inc..
View insider buying and selling activity for Gelesis
or or view top insider-buying stocks.

How do I buy shares of Gelesis?

Shares of GLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Gelesis' stock price today?

One share of GLS stock can currently be purchased for approximately $1.60.

How much money does Gelesis make?

Gelesis (NYSE:GLS) has a market capitalization of $115.82 million and generates $11.19 million in revenue each year.

How many employees does Gelesis have?

Gelesis employs 2 workers across the globe.

How can I contact Gelesis?

Gelesis' mailing address is 405 WEST 14TH STREET, AUSTIN TX, 78701. The official website for Gelesis is capstarspac.com. The company can be reached via phone at 512-340-7800 or via email at 0.

This page (NYSE:GLS) was last updated on 6/26/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.